E. Sheldon-Waniga

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia

K. Venkatakrishnan, D. Mould, Xiaofei Zhou, 2017, British journal of clinical pharmacology.

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

F. Bosch, L. Gordon, J. Radford, 2016 .

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

K. Nackaerts, Siân Jones, A. Chiang, 2020 .

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.

K. Nackaerts, Siân Jones, A. Chiang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)

K. Nackaerts, T. Owonikoko, D. Spigel, 2016 .

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

K. Venkatakrishnan, R. Kurzrock, I. Ray-Coquard, 2019, JAMA oncology.

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

J. Leonard, F. d'Amore, K. Venkatakrishnan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

S. Groshen, J. Friedberg, K. Venkatakrishnan, 2018, Clinical Cancer Research.

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

K. Nackaerts, T. Owonikoko, D. Spigel, 2017 .